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Fig 2. Variation in metabolite level by thrombus size.
Fig. Adjusted Trends in Ruptured Aortic Aneurysm.
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deep venous thrombosis (DVT), but the underlying mechanism(s) re-
main(s) undeﬁned. Metabolite proﬁling permits an agnostic approach to
biomarker discovery and lends insight into the mechanistic underpinnings
of clinical phenotypes. We hypothesized that there would be a differenti-
ating metabolite signature of age-related DVT.
Methods: We subjected heparinized whole blood samples from
young (10 weeks) and old (12-24 months) mice undergoing DVT via elec-
trolytic inferior vena cava-generated thrombosis or nonthrombosed controls
to MeOH:CHCl3 extraction and assayed the resulting aqueous fractions by
one-dimensional 1H-nuclear magnetic resonance (NMR). Metabolites were
identiﬁed and quantiﬁed from spectra using a known concentration of an in-
ternal standard and Chenomx NMR suite software. The data were normal-
ized and compared across groups by analysis of variance with Holm-Sidak
post-testing. Signiﬁcant metabolites were entered into the bioinformatics
platform, Metscape 2, to generate compound-reaction-enzyme-gene
networks.
Results: Glutamine, phenylalanine, and proline were uniquely
elevated in aged DVT+ mice compared with age-matched controls and
young DVT+ mice (Fig 1). These metabolite levels varied in the presence
thrombosis but were not associated with thrombus size (Fig 2). Trimethyl-
amine N-oxide (TMAO) levels were elevated in aged mice (aged vs young
control, P ¼ .004; aged vs young DVT, P ¼ .001), but were not different
between controls and DVT animals. The three metabolite pathways mapped
to a single Metscape network.
Conclusions: One-dimensional 1H-NMR-metabolite proﬁling iden-
tiﬁed, for the ﬁrst time in experimental DVT, three metabolites, gluta-
mine, phenylalanine, and proline, in related pathways, that were
associated with age-related DVT. Although previous data are scarce, these
ﬁndings suggest that a disruption of metabolism involved in redox balance
and inﬂammation contribute to the mechanistic underpinnings of age-
related DVT. Conversely, TMAO levels, which have previously been
shown to be associated with atherosclerosis, were attributable to age but
not DVT. These ﬁndings introduce a new avenue of investigation intovenous thrombosis pathogenesis using metabolomics to inform mecha-
nistic pathways of age-related DVT and to drive biomarker discovery in
the clinic.
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Objectives: The prevalence of abdominal aortic aneurysm (AAA) has
been shown to be declining in the United States. The causes of this trend
are uncertain but have been hypothesized to be the result of changes in
demographics and the prevalence of risk factors. Whether these factors
have had similar effects on trends in thoracic aortic (TAA) and thoracoab-
dominal aneurysm (TAAA) prevalence is unclear. We hypothesized that
presentations with AAA, TAA, and TAAA rupture might exhibit different
trends.
Methods: We searched the Nationwide Inpatient Sample (2006-
2011) for cases of ruptured TAA, AAA, or TAAA in patients aged
$60 years. We estimated the associations of calendar year with the inci-
dence of aortic aneurysm, in aggregate and by type, using logistic regres-
sions, with and without adjustment for demographic and comorbid
factors.
Results: A weighted sample of 43,559 ruptured aortic aneurysms
was identiﬁed. The distribution of cases was 13.6% for TAA, 81.0%
for AAA, and 5.4% for TAAA. In unadjusted analysis, the average annual
trend in ruptured aortic aneurysm was 3.4% (95% conﬁdence interval,
5.4% to 1.4%), but trends varied by type of aneurysm: average annual
trends were 0.8% (5.1% to +3.7%) for TAA, 3.9% (5.9% to 1.9%) for
AAA, and 1.9% (8.0% to +4.6%) for TAAA. After adjustment for demo-
graphic and comorbid factors, the average annual trend in ruptured
aortic aneurysm attenuated to 2.2% (4.3% to 0.2%); by type of aneu-
rysm, the average annual trends were 0.3% (4.8% to +4.4%) for TAA,
2.7% (4.6% to 0.6%) for AAA, and 0.5% (6.7% to +6.2%) for TAAA
(Fig).
Conclusions: Between 2006 and 2011, hospitalization for ruptured
aortic aneurysm tended to decrease annually in the United States. How-
ever, the decrease was almost entirely attributable to a decline in
ruptured AAA. There were no signiﬁcant declines in ruptured TAA or
ruptured TAAA during the study era. Thus, factors contributing to the
decline in ruptured AAA do not appear to have had similar effects on
ruptured TAA or ruptured TAAA.
Fig 2. Secondary patency rates by KM analysis were 93.8% at 12 months,
93.8% at 24 months, and 89.3% at 36 months.
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Objectives: Women are under-represented in trials that set guidelines
for aortic aneurysm management. Several studies reported inferior outcomes
in women compared with men after endovascular aneurysm repair (EVAR).
We investigated the relationship between gender and outcomes after EVAR.
Methods: A total of 1380 consecutive patients underwent elective
EVAR from 1992 to 2012. Baseline, intraoperative, and postoperative vari-
ables were analyzed from a prospective database.
Results: The cohort consisted of 214 women (15.5%) and 1166 men
(84.5%). Women were older than men at repair (77.8 vs 74.5 years; P <
.001) and had less cardiac disease (P ¼ .005). They had shorter (19.8 6
12.9 mm vs 26.3 6 14.7 mm; P < .001), more angulated aortic necks
(38.8 6 16.1 vs 31.2 6 14.7; P < .001) and fewer iliac aneurysms (P ¼
.002). Women had more arterial reconstructions (iliac conduits, P ¼ .006;
thrombolysis and thrombectomy,P¼ .013; patch angioplasty, P< .001; end-
arterectomy,P< .001),more perioperative complications (11.2% vs 6.3%;P¼
.009), and in-hospital days (4.1 days vs 3.4 days;P¼ .029). Perioperativemor-
tality was equivalent (women: 2% vsmen: 2.3%;P¼ .73).Mean follow-upwas
30.9 months. Women and men experienced equivalent endoleaks, arterial
reinterventions, aneurysm-related deaths, and overall survival.
Conclusions: Female gender is associated with more periprocedural
complications; however, it does not affect long-term reinterventions or survival.
Further studies are warranted to elucidate the effect of gender on outcomes.
This data should be considered when selecting EVAR for men and women.
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2University of Arkansas, Little Rock, ArkFig 1. Primary patency rates by KM analysis were 85.6% at 12 months,
83.1% at 24 months, and 76.7% at 36 months.Objectives: The Supera stent (Abbott Laboratories, Abbott Park, Ill)
has a unique biomimetic design allowing for axial and longitudinal ﬂexibility
and fracture resistance. The aim of this retrospective study was to assess the
midterm primary patency of Supera stents used to treat patients with super-
ﬁcial femoral and popliteal arterial disease by a single practice.
Methods: From April 2010 to December 2011, 48 patients and 54
limbs with symptomatic femoropopliteal lesions underwent angioplasty
and stenting with the Supera stent. Five patients had no follow-up and
were excluded. Patient demographics, radiographic imaging, lesion mor-
phologies, procedural reports, reinterventions, and follow-up clinical visit
notes were reviewed. Primary patency was deﬁned as clinical resolution of
symptoms and no secondary intervention. The 12-, 24-, and 36-month pri-
mary and secondary patency rates were estimated using Kaplan-Meier
analysis.
Results: A total of 48 consecutive patients (42 males, six females),
54 limbs, mean age 64.3 years (range, 51-87 years) received Supera stents as
part of their treatment for femoropopliteal disease.Primary indications for inter-
vention included claudication, rest pain, and tissue loss at rates of 54% (29 of
54), 26% (14 of 54), and 20% (11 of 54), respectively. Twenty-two percent
of lesions were TransAtlantic Inter-Society Consensus (TASC) A or B, and
78% were C or D. Mean lesion length was 24.0 cm (range, 3-51 cm). Mean
follow-up was 27.5 months (range, 1-45). The ankle-brachial index increased
from 0.58 6 0.20 preoperatively to 0.77 6 0.18 postoperatively (P ¼
.00004). Primary, primary assisted, and secondary patency rates at the latest
follow-up were 79.6%, 88.9%, and 92.3%, respectively (Table). Long lesions
>30 cm (33%; 18/54) had primary, primary-assisted, and secondary patency
rates at latest follow-upof 83%, 89%, and 94%, respectively.Cumulative primary
patency rates by Kaplan-Meier analysis at 12, 24, and 36 months was 85.6%,
83.1%, and 76.7%, respectively (Fig 1). Secondary patency rates by Kaplan-
Meier estimates at 12, 24, and 36 months were 93.8%, 93.8%, and 89.3%,
respectively (Fig 2). No stent fractures were found at clinical follow-up.
Conclusions: Our midterm results show that Supera stents are dura-
ble in treating femoropopliteal lesions, with notably high patency rates in
long lesions.
Table. Patency rates as a function of lesion length
1-15 cm 16-30 cm >30 cmPatency
(n ¼ 18),
No. (%)(n ¼ 18),
No. (%)(n ¼ 18),
No. (%)Primary patency 13 (72.2) 15 (83.3) 15 (83.3)
Primary-assisted patency 16 (88.9) 16 (88.9) 16 (88.9)
Secondary patency 17 (94.4) 16 (88.9) 17 (94.4)
